MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Pharmacotherapy"

  • 2024 International Congress

    Contribution to Efficacy by Active Metabolites of Suvecaltamide in a Preclinical Rat Model of Essential Tremor

    N. Shanks, S. Markova, R. Mukkavilli, L. Tan, M. Lee, E. Brigham (Palo Alto, USA)

    Objective: Present the pharmacokinetic/pharmacodynamic (PK/PD) relationship and contribution to anti-tremor efficacy for suvecaltamide and its active metabolites (JZZ05000034=M01, JZZ05000035=M02) in a harmaline-induced rat model of…
  • 2024 International Congress

    The Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons with REM Sleep Behavior Disorder (RBD)

    J. Cedarbaum, B. Koo, L. Zhang, K. Mead, S. Patel, V. Reddy, D. Hafler (New Haven, USA)

    Objective: To explore the potential for an immunologically based intervention to slow evolution of symptoms in persons with prodromal or Stage 2b (Simuni et al.…
  • 2024 International Congress

    Treatment Patterns in Essential Tremor: Real-World Evidence from Germany

    JS. Becktepe, S. Müller, T. Wilke, E. Zhuleku, K. Appiah, K. Mcdonald, N. Dzimitrowicz, J. Marshall, J. Sabater, LM. Barbato, TA. Saifee (Kiel, Germany)

    Objective: To investigate the treatment patterns (TP), healthcare resource utilization (HCRU), and costs of essential tremor (ET) in a real-world setting in Germany using insurance…
  • 2024 International Congress

    Effect of the mGlu2 positive allosteric modulator biphenyl-indanone A on parkinsonian disability in the 6-hydroxydopamine-lesioned rat

    W. Kang, Y. Kulkarni, I. Frouni, C. Kwan, D. Bédard, P. Huot (Montreal, Canada)

    Objective: To evaluate the effect of biphenyl-indanone A (BINA), a metabotropic glutamate 2 (mGlu2) receptor positive allosteric modulator (PAM), on parkinsonian disability in the 6-OHDA-lesioned…
  • 2024 International Congress

    Effect of various mGlu2 and mGlu2/3 activators on parkinsonism: a sub-analysis in the MPTP-lesioned primate

    W. Kang, I. Frouni, S. Nuara, C. Kwan, J. Gourdon, D. Bédard, P. Huot (Montreal, Canada)

    Objective: To evaluate the effect of the metabotropic glutamate 2/3 (mGlu2/3) orthosteric activators (OAs) LY-354,740 and LY-404,039, as well as the effects of the metabotropic…
  • 2024 International Congress

    Characterisation of the pharmacokinetic profile of amantadine in the common marmoset

    D. Bédard, F. Gaudette, S. Nuara, F. Beaudry, P. Huot (Montreal, Canada)

    Objective: To determine the pharmacokinetic (PK) profile of amantadine in the common marmoset (Callithrix jacchus). Background: Amantadine is currently approved for the treatment of L-3,4-dihydroxyphenylalanine…
  • 2024 International Congress

    Neuroprotective Action of Betulin in Parkinson’s disease: Alleviating Mitochondrial Dysfunction and Oxidative Stress-Induced Apoptosis in rat model

    A. Kumar (Allahabad, India)

    Objective: The objective of this study was to evaluate the neuroprotective efficacy of Betulin in MPTP-induced mice models of Parkinson's disease (PD), focusing on its…
  • 2024 International Congress

    Dose-dependent alterations of lysosomal activity and alpha-synuclein level in peripheral blood monocyte-derived macrophages and SH-SY5Y neuroblastoma cell line by upon inhibition of mTOR kinase activity

    A. Bezrukova, K. Basharova, G. Baydakova, E. Zakharova, S. Pchelina, T. Usenko (Gatchina, Russian Federation)

    Objective: To evaluate the perceptivity of mTOR kinase activity inhibition for Parkinson's disease therapy (PD). Background: The protein kinase mTOR is currently considered as a…
  • 2024 International Congress

    Adherence and Persistence Among Patients with Parkinson’s Disease Initiating Istradefylline: 12-Month Follow-Up from US Real-World Data

    R. Joseph, J. Qian, H. Cummings, Y. Chen, S. Tewari, M. Soileau (Columbus, USA)

    Objective: To evaluate 12-month adherence and persistence and identify factors associated with persistence among Parkinson’s disease (PD) patients initiating istradefylline, the first non-dopaminergic adjunct targeting…
  • 2024 International Congress

    Carbidopa does not cause changes in QTc interval even at a supratherapeutic dose

    R. Kleiman, J. Mickelson, R. Sanwo, C. Edwards, S. Fisher, H. Visser (South Gate, USA)

    Objective: To assess the cardiac safety of a single supratherapeutic dose of carbidopa in healthy adults. Background: Carbidopa has been approved for use in combination…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 34
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley